Tag: Mark Lane

Impact of 21st Century Cures Act

Congress recently passed the 21st Century Cures Act with $4.8 billion dollars in funding and a purpose of speeding the development and approval of new medicines and medical devices the act has generated significant excitement and discussion.  Some of the key components of the legislation include: $4.8 billion dollars additional...

Read More

Friends or Enemies: Process Improvement and Innovation in the Pharmaceutical Industry

“Process stifling our innovation”!  “These extra meetings slow down our decision-making”! “Project management is distracting us from the real work that needs to get done”! “We have zero flexibility”! Unfortunately, these are commonly held beliefs in many organizations that believe having process discipline and rigor negatively impact productivity.  Consider what...

Read More

The Hammers and Nails of R&D Portfolio Management:  A Fool With a Tool is Still a Fool 

After attending a recent R&D portfolio and resource management conference, and listening to presenters from both large, established, and rising star pharmaceutical companies and life science organizations, we were surprised to hear how many companies were grappling with issues related to transparency and consistency of data, the ability to drive...

Read More

Eliminating Silos: Embracing Customer Centricity in Drug Development

“Customer centricity”, “patient engagement”, and “patient-focus” are popular buzzwords in the pharmaceutical industry as companies try to adapt to an ever-evolving customer landscape.  It’s been predicted that patient engagement is the next big movement in the industry – and it truly is.  Of course, there are multiple approaches to ensuring...

Read More

Archives